Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-10-24 |
2024-09 |
-0.01 |
N/A |
N/A |
N/A |
2024-08-06 |
2024-06 |
-0.03 |
N/A |
N/A |
N/A |
2024-05-14 |
2024-03 |
-0.04 |
N/A |
N/A |
N/A |
2024-03-07 |
2023-12 |
0.02 |
N/A |
N/A |
N/A |
2023-10-26 |
2023-09 |
-0.41 |
N/A |
N/A |
N/A |
2023-08-10 |
2023-06 |
0.06 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-08-13 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-06-11 |
Alliance Global Partners |
Upgrade |
Neutral |
Buy |
2023-05-24 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-05-18 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-05-15 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-04-02 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2023-03-23 |
ASHMAN PHILIP |
Chief Operating Officer |
133.32K |
Stock Award(Grant) |
2023-09-13 |
CALIGAN PARTNERS L,P. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2023-10-01 |
EISWIRTH RICHARD S JR |
Chief Executive Officer |
722.52K |
Stock Award(Grant) |
2023-03-23 |
HOLLAND DAVID R |
Officer |
108.88K |
Stock Award(Grant) |
2022-10-30 |
JONES JOHN PHILIP |
Chief Financial Officer |
32.19K |
Stock Award(Grant) |
2023-08-14 |
MORGAN ADAM |
Director and Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Conversion of Exercise of derivative security |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Velan Capital Investment Management LP |
1.66M |
4.85M |
18.86% |
2023-06-29 |
Morgan Stanley |
666.25K |
1.95M |
7.57% |
2023-06-29 |
Caligan Partners, LP |
478.78K |
1.40M |
5.44% |
2023-06-29 |
Healthcare of Ontario Pension Plan Trust Fund |
250.00K |
730.00K |
2.84% |
2023-06-29 |
Vanguard Group Inc |
141.39K |
412.87K |
1.61% |
2023-06-29 |
Renaissance Technologies, LLC |
129.72K |
378.77K |
1.47% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
87.15K |
254.47K |
0.99% |
2023-06-29 |
Vanguard Extended Market Index Fund |
54.25K |
158.40K |
0.62% |
2023-06-29 |
Bridgeway Funds Inc-Ultra Small Company Market Fund |
20.00K |
58.40K |
0.23% |
2023-06-29 |
Bridgeway Funds Inc-Ultra Small Company Fund |
18.30K |
53.44K |
0.21% |
2023-05-30 |
Fidelity Extended Market Index Fund |
13.79K |
37.91K |
0.16% |
2023-05-30 |
Fidelity Total Market Index Fund |
13.04K |
35.85K |
0.15% |
Split |
Date |
1 : 15 |
2019-11-15 |